Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

By sjmartinez • March 27, 2025

Channick R, Medrek S, Delcroix M, Gaine S, Jansa P, Lang I, McLaughlin V, Mehta S, Pulido T, Sastry B, Souza R, Torbicki A, Zhao C, Strachan P, Agron P, Yen J, Sitbon O. Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension. JHLT Open. 2025 Jan 16;7:100197. doi: 10.1016/j.jhlto.2024.100197. PMID: 40144855; PMCID: PMC11935431.

Tags: GRIPHON, Macitentan, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, Selexipag, SERAPHIN

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li[...]

Drug Development

Cole GM, Zhu C, Manglani K, Hou K, Bombino A, Jones M, Eisenberg DS, Frautschy SA. Drug Development. Alzheimers Dement. 2025 Dec;21 Suppl 5:e106249. doi:[...]

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E,[...]